623 related articles for article (PubMed ID: 28303260)
1. Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.
Voutilainen MH; De Lorenzo F; Stepanova P; Bäck S; Yu LY; Lindholm P; Pörsti E; Saarma M; Männistö PT; Tuominen RK
eNeuro; 2017; 4(1):. PubMed ID: 28303260
[TBL] [Abstract][Full Text] [Related]
2. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.
Voutilainen MH; Bäck S; Peränen J; Lindholm P; Raasmaja A; Männistö PT; Saarma M; Tuominen RK
Exp Neurol; 2011 Mar; 228(1):99-108. PubMed ID: 21185834
[TBL] [Abstract][Full Text] [Related]
3. Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease.
Huotarinen A; Penttinen AM; Bäck S; Voutilainen MH; Julku U; Piepponen TP; Männistö PT; Saarma M; Tuominen R; Laakso A; Airavaara M
Neuroscience; 2018 Mar; 374():250-263. PubMed ID: 29408408
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
[TBL] [Abstract][Full Text] [Related]
5. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease.
Voutilainen MH; Bäck S; Pörsti E; Toppinen L; Lindgren L; Lindholm P; Peränen J; Saarma M; Tuominen RK
J Neurosci; 2009 Jul; 29(30):9651-9. PubMed ID: 19641128
[TBL] [Abstract][Full Text] [Related]
6. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
Aoi M; Date I; Tomita S; Ohmoto T
Neurosci Res; 2000 Apr; 36(4):319-25. PubMed ID: 10771110
[TBL] [Abstract][Full Text] [Related]
7. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.
Lindholm P; Voutilainen MH; Laurén J; Peränen J; Leppänen VM; Andressoo JO; Lindahl M; Janhunen S; Kalkkinen N; Timmusk T; Tuominen RK; Saarma M
Nature; 2007 Jul; 448(7149):73-7. PubMed ID: 17611540
[TBL] [Abstract][Full Text] [Related]
8. AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model.
Ren X; Zhang T; Gong X; Hu G; Ding W; Wang X
Exp Neurol; 2013 Oct; 248():148-56. PubMed ID: 23764500
[TBL] [Abstract][Full Text] [Related]
9. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
[TBL] [Abstract][Full Text] [Related]
10. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
11. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor.
Kirik D; Rosenblad C; Björklund A
Eur J Neurosci; 2000 Nov; 12(11):3871-82. PubMed ID: 11069582
[TBL] [Abstract][Full Text] [Related]
12. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
14. The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA.
Konieczny J; Czarnecka A; Lenda T; Kamińska K; Antkiewicz-Michaluk L
Neuroscience; 2017 Jan; 340():308-318. PubMed ID: 27826109
[TBL] [Abstract][Full Text] [Related]
15. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
16. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
Jalewa J; Sharma MK; Gengler S; Hölscher C
Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
[TBL] [Abstract][Full Text] [Related]
17. Cinnamon and its Metabolite Protect the Nigrostriatum in a Mouse Model of Parkinson's Disease Via Astrocytic GDNF.
Patel D; Jana A; Roy A; Pahan K
J Neuroimmune Pharmacol; 2019 Sep; 14(3):503-518. PubMed ID: 31119595
[TBL] [Abstract][Full Text] [Related]
18. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
[TBL] [Abstract][Full Text] [Related]
19. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine.
Tseng JL; Baetge EE; Zurn AD; Aebischer P
J Neurosci; 1997 Jan; 17(1):325-33. PubMed ID: 8987758
[TBL] [Abstract][Full Text] [Related]
20. Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.
Requejo C; Ruiz-Ortega JA; Bengoetxea H; Garcia-Blanco A; Herrán E; Aristieta A; Igartua M; Ugedo L; Pedraz JL; Hernández RM; Lafuente JV
Mol Neurobiol; 2015 Oct; 52(2):846-58. PubMed ID: 26041662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
